Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Thomssen

Showing results (61-70 of 71) with videos related to

Pageof 8
Sort By:
Breast Cancer Research and Treatment|August 20, 2017
BRCA1-like profile is not significantly associated with survival benefit of non-myeloablative intensified chemotherapy in the GAIN randomized controlled trialA G J van Rossum, P C Schouten, K E Weber, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 8, 2010
First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an open-label study in 2,251 patientsI E Smith, J-Y Pierga, L Biganzoli, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 16, 2014
Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expressionU Nitz, O Gluz, J Huober, et al.
Geburtshilfe Und Frauenheilkunde|July 14, 2015
Primary Therapy of Patients with Early Breast Cancer: Evidence, Controversies, Consensus: Opinions of German Specialists to the 14th St. Gallen International Breast Cancer Conference 2015 (Vienna 2015)M Untch, N Harbeck, J Huober, et al.
Breast (Edinburgh, Scotland)|March 20, 2012
1st International consensus guidelines for advanced breast cancer (ABC 1)F Cardoso, A Costa, L Norton, et al.
ESMO Open|June 5, 2025
Quality-of-life and symptom severity in the PALLAS randomized trial of palbociclib with adjuvant endocrine therapy in early breast cancer (AFT-05, ABCSG-42, BIG-14-03, PrE0109)M J Naughton, D M Zahrieh, M Gnant, et al.
Breast (Edinburgh, Scotland)|January 21, 2020
Complementary and alternative medicine and musculoskeletal pain in the first year of adjuvant aromatase inhibitor treatment in early breast cancer patientsC C Hack, L Häberle, S Y Brucker, et al.
Geburtshilfe Und Frauenheilkunde|January 9, 2015
Evaluation of Therapy Management and Patient Compliance in Postmenopausal Patients with Hormone Receptor-positive Breast Cancer Receiving Letrozole Treatment: The EvaluateTM StudyP A Fasching, T Fehm, S Kellner, et al.
European Journal of Cancer (Oxford, England : 1990)|April 22, 2018
Influence of side-effects on early therapy persistence with letrozole in post-menopausal patients with early breast cancer: Results of the prospective EvAluate-TM studyN Nabieva, T Fehm, L Häberle, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 19, 2017
Influence of patient and tumor characteristics on early therapy persistence with letrozole in postmenopausal women with early breast cancer: results of the prospective Evaluate-TM study with 3941 patientsN Nabieva, S Kellner, T Fehm, et al.
Pageof 8

Showing results (61-70 of 71) with videos related to

Sort By:
Pageof 8
Breast Cancer Research and Treatment|August 20, 2017
BRCA1-like profile is not significantly associated with survival benefit of non-myeloablative intensified chemotherapy in the GAIN randomized controlled trialA G J van Rossum, P C Schouten, K E Weber, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 8, 2010
First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an open-label study in 2,251 patientsI E Smith, J-Y Pierga, L Biganzoli, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 16, 2014
Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expressionU Nitz, O Gluz, J Huober, et al.
Geburtshilfe Und Frauenheilkunde|July 14, 2015
Primary Therapy of Patients with Early Breast Cancer: Evidence, Controversies, Consensus: Opinions of German Specialists to the 14th St. Gallen International Breast Cancer Conference 2015 (Vienna 2015)M Untch, N Harbeck, J Huober, et al.
Breast (Edinburgh, Scotland)|March 20, 2012
1st International consensus guidelines for advanced breast cancer (ABC 1)F Cardoso, A Costa, L Norton, et al.
ESMO Open|June 5, 2025
Quality-of-life and symptom severity in the PALLAS randomized trial of palbociclib with adjuvant endocrine therapy in early breast cancer (AFT-05, ABCSG-42, BIG-14-03, PrE0109)M J Naughton, D M Zahrieh, M Gnant, et al.
Breast (Edinburgh, Scotland)|January 21, 2020
Complementary and alternative medicine and musculoskeletal pain in the first year of adjuvant aromatase inhibitor treatment in early breast cancer patientsC C Hack, L Häberle, S Y Brucker, et al.
Geburtshilfe Und Frauenheilkunde|January 9, 2015
Evaluation of Therapy Management and Patient Compliance in Postmenopausal Patients with Hormone Receptor-positive Breast Cancer Receiving Letrozole Treatment: The EvaluateTM StudyP A Fasching, T Fehm, S Kellner, et al.
European Journal of Cancer (Oxford, England : 1990)|April 22, 2018
Influence of side-effects on early therapy persistence with letrozole in post-menopausal patients with early breast cancer: Results of the prospective EvAluate-TM studyN Nabieva, T Fehm, L Häberle, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 19, 2017
Influence of patient and tumor characteristics on early therapy persistence with letrozole in postmenopausal women with early breast cancer: results of the prospective Evaluate-TM study with 3941 patientsN Nabieva, S Kellner, T Fehm, et al.
Pageof 8